The U.S. Supreme Court has agreed to review a Federal Circuit Court of Appeals ruling on the patentability of human genes and limited its grant of certiorari to the question “Are human genes patentable?” The Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 12-398 (U.S., cert. granted November 30, 2012). The Federal Circuit’s decision, affirming its earlier ruling in the wake of Mayo Collaborative Services v. Prometheus, Inc., 132 S. Ct. 1289 (2012), concluded that isolated DNA molecules were patent eligible and that most of Myriad’s “method claims” for comparing molecules to determine whether a patient’s genes have mutations that could cause breast and ovarian cancer were not patent eligible. Further details about its August 2012 ruling appear in Issue 41 of this Bulletin. The American Civil Liberties Union is representing the parties that filed the petition for a writ of certiorari.